期刊
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
卷 7, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fbioe.2019.00352
关键词
mesenchymal stromal cells; stem cells; MSCs; secretome; extracellular vesicles; cell therapy; bone tissue engineering; bone regeneration
资金
- European Regional Development Fund Interreg V-A Italia-Austria 2014-2020 [EXOTHERA IT-AT 1036]
- Project ExtraNeu from the State of Salzburg, Austria
- project RejuvenateBone from European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant [657716]
- Marie Curie Actions (MSCA) [657716] Funding Source: Marie Curie Actions (MSCA)
Effective regeneration of bone defects often presents significant challenges, particularly in patients with decreased tissue regeneration capacity due to extensive trauma, disease, and/or advanced age. A number of studies have focused on enhancing bone regeneration by applying mesenchymal stromal cells (MSCs) or MSC-based bone tissue engineering strategies. However, translation of these approaches from basic research findings to clinical use has been hampered by the limited understanding of MSC therapeutic actions and complexities, as well as costs related to the manufacturing, regulatory approval, and clinical use of living cells and engineered tissues. More recently, a shift from the view of MSCs directly contributing to tissue regeneration toward appreciating MSCs as cell factories that secrete a variety of bioactive molecules and extracellular vesicles with trophic and immunomodulatory activities has steered research into new MSC-based, cell-free therapeutic modalities. The current review recapitulates recent developments, challenges, and future perspectives of these various MSC-based bone tissue engineering and regeneration strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据